MedPath

Crenezumab

Generic Name
Crenezumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1095207-05-8
Unique Ingredient Identifier
O8AS5277H0
Background

Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.

Associated Conditions
-
Associated Therapies
-
biospace.com
·

7 Alzheimer's and Parkinson's Programs Discarded in 2024

Despite approvals for Leqembi and Kisunla, attrition in Alzheimer’s and Parkinson’s pipelines persists, with Roche, Johnson & Johnson, Sage Therapeutics, and Otsuka discontinuing programs. Analysts attribute these decisions to clinical trial data and evolving commercial opportunities, noting the Alzheimer’s market is projected to be worth $15.5 billion by 2031, while Parkinson’s drugs are expected to reach $6.63 billion by 2029.
dovepress.com
·

Prevention and treatment strategies for Alzheimer's disease: Focusing

Alzheimer’s disease (AD) involves progressive neurodegeneration, characterized by cognitive decline and accumulation of β-amyloid protein (Aβ) and neurofibrillary tangles (NFTs). Neuroinflammation, driven by microglia and astrocytes, plays a crucial role in AD pathogenesis. Microglia phagocytose Aβ but can exacerbate disease if overactivated. Astrocytes, though protective, can contribute to neuroinflammation and Aβ production when reactive. Current treatments, including monoclonal antibodies targeting Aβ, show promise but do not reverse disease. Future research aims to mitigate neuroinflammation and enhance protective microglia-astrocyte interactions for potential AD therapies.

The amyloid hypothesis of Alzheimer's disease at 25 years

The amyloid β‐protein (Aβ) hypothesis suggests an imbalance in Aβ42 production and clearance initiates Alzheimer's disease (AD). Evidence includes genetic mutations in APP and presenilin, Aβ's role in Down's syndrome, and its impact on synapses and memory. Aβ antibodies show potential in slowing cognitive decline, supporting Aβ as a therapeutic target.
© Copyright 2025. All Rights Reserved by MedPath